Latest Alkaloids Stories
Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor Cells and Reductions in Tumor Markers BOTHELL, WA, and VANCOUVER, June 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
CHICAGO, June 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, May 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
PHILADELPHIA, May 6 /PRNewswire/ -- URL Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has issued new label information affecting all approved protease inhibitors for treatment of HIV when co-administered with ColcrysÂ® (colchicine, USP).
PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC...
CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors.
PHILADELPHIA, March 31 /PRNewswire/ -- A newly-published clinical study demonstrates that ColcrysÂ® (colchicine, USP), a low-dose oral colchicine, is just as effective as high-dose colchicine in reducing pain associated with early acute gout flare, but with a safety profile statistically indistinguishable from placebo. The study, "High vs.
PHILADELPHIA, March 15 /PRNewswire/ -- URL Pharma, Inc. today announced the launch of an expanded ColcrysÂ® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy.
CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- Withering but not falling off, as a blossom that persists on a twig after flowering.